SCHEMBL664705

SCHEMBL664705

COc1ccc(N(C)S(=O)(=O)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.68
TAS2R14 Q9NYV8 4/20 0.63
HPGD P15428 4/20 0.62
ALDH1A1 P00352 3/20 0.62
MAPT P10636 4/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
LMNA P02545 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.60
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
PTGES O14684 1/20 0.59
TAS2R8 Q9NYW2 1/20 0.59
CXCR3 P49682 1/20 0.59
KDM4E B2RXH2 1/20 0.58
MAPK1 P28482 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5622356 0.87 PGR (0.79) PGRHPGDALDH1A1MAPTMEN1
SCHEMBL15482244 0.85 HPGD (0.69) PGRHPGDALDH1A1MAPTMEN1
SCHEMBL665429 0.83 TAS2R14 (0.60) PGRTAS2R14ALDH1A1PTGESTAS2R8
SCHEMBL15953453 0.83 MAPK1 (0.69) PGRALDH1A1MAPTMEN1KMT2A
SCHEMBL11441218 0.83 MAPT (0.74) TAS2R14HPGDALDH1A1MAPTMEN1
SCHEMBL13190025 0.83 ALDH1A1 (0.62) TAS2R14ALDH1A1MAPTMEN1KMT2A
SCHEMBL10186886 0.83 L3MBTL1 (0.83) PGRALDH1A1MAPTMEN1KMT2A
SCHEMBL664209 0.83 CA12 (0.67) TAS2R14ALDH1A1MAPTMEN1KMT2A
SCHEMBL3718777 0.83 NR1I2 (0.62) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL7267305 0.83 PGR (0.82) PGRALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-20230110928-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2023-04-13 US disclosed
US-11512081-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2022-11-29 US disclosed
US-20210188835-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2021-06-24 US disclosed
US-20210188835-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2021-06-24 US disclosed
US-10975067-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
US-10975067-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
EP-3626240-A1 PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP StemSynergy Therapeutics, Inc. (US) 2020-03-25 EP disclosed
EP-3626240-A1 PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP StemSynergy Therapeutics, Inc. (US) 2020-03-25 EP disclosed
US-9416101-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2016-08-16 US disclosed
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2015-02-19 US disclosed
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2015-02-19 US disclosed
US-8901306-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-8901306-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2012-02-23 US disclosed
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2012-02-23 US disclosed
EP-2403499-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL Stemsynergy Therapeutics, Inc (US) 2012-01-11 EP disclosed
WO-2010101964-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2010-09-10 WO disclosed
WO-2010101964-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885
US-10975067-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885
US-20230110928-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885
US-11512081-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885
US-20210188835-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 PGR 2953/4885TAS2R14 4732/4885HPGD 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.